[Featured Stock] Samsung Biologics Reclaims 'Emperor Stock' Status After 3 Years

Samsung Biologics has reclaimed its position as a "Hwangjeju," meaning a stock priced over 1 million KRW per share, for the first time in three years.

As of 9:45 AM on the 27th, Samsung Biologics is trading at 990,000 KRW on the KOSPI market, up 28,000 KRW (2.91%) from the previous close.

The trading volume is approximately 147,000 shares, with a trading value of 146.6 billion KRW.

On this day, Samsung Biologics reached an intraday high of 1,005,000 KRW, setting a new 52-week high and surpassing the 1 million KRW mark to ascend as a Hwangjeju. This is the first time it has exceeded 1 million KRW since August 23, 2021 (closing price of 1,009,000 KRW).

This also signifies the return of a "Hwangjeju" to the stock market. The title had been vacant since EcoPro recorded 1,026,000 KRW on the KOSDAQ market on September 11 of last year.

The main factor is attributed to the remarkable recent performance. Samsung Biologics’ consolidated operating profit for the second quarter of this year increased by 71.45% year-on-year to 434.5 billion KRW, and sales rose by 33.56% to 1.1569 trillion KRW.

The intensifying conflict between the U.S. and China, which is reshaping the global pharmaceutical supply chain, is also seen as a positive factor for domestic contract development and manufacturing organizations (CDMOs).

Researcher Choi Seong-hwan from ResearchAlum explained in a report yesterday, "The U.S. Biosecure Act is scheduled for a House vote this September," adding, "It aims to strengthen the protection of technology and biological resources."

He continued, "It strictly limits the overseas transfer of bio technology," and added, "Global pharmaceutical companies in the U.S. and Europe are paying attention to domestic CDMO companies like Samsung Biologics, which possess technical capabilities and production capacity."